Reuters reviews.

Bristol-Myers Squibb receives FDA approval for new formulation of antiretroviral Reyataz Bristol-Myers Squibb on Friday announced that it all has received FDA authorization for a single 300 mg capsule formulation of it is protease inhibitor Reyataz to be studied within combination therapy, Reuters reviews. The new formulation is taken once daily and likely will be accessible within one week, regarding to BMS . Reyataz, known as atazanavir generically, is used in second-collection HIV/AIDS prescription drugs . Under World Health Organization guidelines, atazanavir is best used with a booster drug, generally Abbott Laboratories’ ritonavir .

Related Articles

Other Articles from "doctor":